Analyse de l'application TELLAPRIALBI pour le 23 septembre

The APRI and ALBI scores are commonly used in clinical routine to assess the severity of illness for patients suffering from hepatical tumors and to predict postoperative liver dysfunction after resection. Combining these scores, the APRI+ALBI score provides even better performance of assessment and prediction regarding 30-day-mortality after surgery. TELLAPRIALBI allows you to - enter relevant lab parameters (platelet count, AST, albumin and bilirubin levels) - automatically compute APRI, ALBI and APRI+ALBI scores for comparative review - select from a variety of tumor types together with the respective extent of resection and - view clinical interpretation plots regarding 30-day-mortality post operation highlighting the risk class indicated by the APRI+ALBI score. The app is intended for educational use by medical professionals and to allow review of the APRI+ALBI score and its predictive quality. All information entered into the app and computed by it is processed exclusively within the app on the users device and no information is stored, transmitted or shared by the app. TELLAPRIALBI was developed jointly by the Translational Experimental Liver Laboratory at the Medical University of Vienna (TELLVIENNA) and Howto Health GmbH. It is based on a joint research paper which is currently in print at BMJ Open. The app is published by and the service is provided by Howto Health GmbH.